Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma

Because many patients with unresectable basal cell carcinoma (BCC) are aged ≥65 years, this study explores the efficacy and safety of vismodegib in these patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC) in the ERIVANCE BCC trial and the expanded access study (EAS).We...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Chang, Anne Lynn S., Lewis, Karl D., Arron, Sarah T., Migden, Michael R., Solomon, James A., Yoo, Simon, Day, Bann-Mo, McKenna, Edward F., Sekulic, Aleksandar
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342800/
https://ncbi.nlm.nih.gov/pubmed/27764798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12660
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы